Search

Your search keyword '"Tewari, Krishnansu S."' showing total 13 results
Start Over Author "Tewari, Krishnansu S." Publication Year Range This year
13 results on '"Tewari, Krishnansu S."'

1. Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over

Author

Pitiyarachchi, Omali, Ansell, Peter J., Coleman, Robert L., Dinh, Minh H., Holman, Laura, Leath, Charles A., III, Werner, Theresa, DiSilvestro, Paul, Morgan, Mark, Tew, William, Lee, Christine, Cunningham, Mary, Newton, Meredith, Edraki, Babak, Lim, Peter, Barlin, Joyce, Spirtos, Nicola M., Tewari, Krishnansu S., Edelson, Mitchell, Reid, Thomas, Carlson, Jay, and Friedlander, Michael

Published
2024
Full Text
View/download PDF

5. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Author

Tewari, Krishnansu S., primary, Colombo, Nicoletta, additional, Monk, Bradley J., additional, Dubot, Coraline, additional, Cáceres, M. Valeria, additional, Hasegawa, Kosei, additional, Shapira-Frommer, Ronnie, additional, Salman, Pamela, additional, Yañez, Eduardo, additional, Gümüş, Mahmut, additional, Olivera Hurtado de Mendoza, Mivael, additional, Samouëlian, Vanessa, additional, Castonguay, Vincent, additional, Arkhipov, Alexander, additional, Tekin, Cumhur, additional, Li, Kan, additional, Toker, Sarper, additional, Keefe, Stephen M., additional, and Lorusso, Domenica, additional

Published
2024
Full Text
View/download PDF

6. Pembrolizumab plus chemotherapy with/without bevacizumab in East Asian patients with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis

Author

Kim, Yong Man, primary, Kim, Se Ik, additional, Nishio, Shin, additional, Hasegawa, Kosei, additional, Dubot, Coraline, additional, Cáceres, M. Valeria, additional, Tewari, Krishnansu S., additional, Lorusso, Domenica, additional, Lee, Jeong-Won, additional, Liou, Wen-Shiung, additional, Li, Kan, additional, Tekin, Cumhur, additional, Monk, Bradley J., additional, and Colombo, Nicoletta, additional

Published
2024
Full Text
View/download PDF

9. Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Author

Arend, Rebecca C., Monk, Bradley J., Shapira-Frommer, Ronnie, Haggerty, Ashley F., Alvarez, Edwin A., Amit, Amnon, Alvarez Secord, Angeles, Muller, Carolyn, Casado Herraez, Antonio, Herzog, Thomas J., Tewari, Krishnansu S., Cohen, Joshua G., Huang, Marilyn, Yachnin, Adelya, Holeman, Laura L., Ledermann, Jonathan A., Rachmilewitz Minei, Tamar, Buyse, Marc, Fain Shmueli, Shifra, and Lavi, Michal

Published
2024
Full Text
View/download PDF

10. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.

Author

García, Eduardo, Ayoub, Natalie, and Tewari, Krishnansu S.

Subjects
CERVICAL cancer, METASTASIS, POOR communities, THERAPEUTICS, REGULATORY approval
Abstract

Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence. The tolerability of these novel medicines and associated durable responses underscore regulatory approval by the U.S. Food and Drug Administrations and their implementation in clinic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results